



Candidate's Name



**HBA-USA Election
Board of Directors 2023-2026**

Professional profile (Expertise, degrees, current position, previous positions)

Expertise

Clinical research professional who has supported medical monitoring activities for phase I/II/III trials MD, Ph.D. scientist with a background in IgAN, Lupus Nephritis, APOL1-mediated kidney diseases, non-opioid analgesics, and lipidology.

Degrees

| | |
|--|------------------|
| Boston University Graduate School of Management | Boston, MA |
| <i>MBA, Concentration in Health Sector Management, Business Strategy and Finance</i> | May 2013 |
| Faculty of Medicine, University of Crete | Iraklion, Greece |
| <i>Ph.D., Molecular Medicine</i> | July 2011 |
| <i>Master of Science, Molecular Medicine</i> | April 2008 |
| <i>Degree of Medicine</i> | July 2005 |

Current and Previous Positions

| | |
|--|-------------------------|
| Alexion Pharmaceuticals, AstraZeneca Rare Disease Unit | Boston, MA |
| <i>Medical Director, Clinical Development Sciences</i> | 07/2022 – Present |
| Vertex Pharmaceuticals, Inc. | Boston, MA; 2012 – 2022 |
| <i>Clinical Scientist Principal, Clinical Science and Site Advocacy</i> | 02/2020 – 07/2022 |
| <i>Sr. Clinical Scientist, Clinical Development Support & Site Advocacy</i> | 07/2018 – 02/2020 |
| <i>Sr. Business Operations Analyst, Process Management and Business Analytics</i> | 07/2017 – 07/2018 |
| <i>Manager, Process Management and Business Analytics</i> | 08/2015 – 07/2017 |
| <i>Manager, Compliance Oversight Systems, within CDE and GMDA</i> | 03/2014 – 08/2015 |
| <i>Sr. Associate, Clinical Development Execution, Contractor</i> | 06/2013 – 01/2014 |
| <i>Clinical Trial Associate, Clinical Compliance and Risk Management, Contractor</i> | 07/2012 – 04/2013 |
| Whitaker Cardiovascular Institute, Boston University, School of Medicine | Boston, MA |
| <i>Research Associate/Graduate Student</i> | 10/2006 – 05/2011 |

Scientific profile (Research interests, publication record, distinctions & awards)

Promote operational excellence in the execution of clinical trials.
Current focus is on IgAN, Lupus Nephritis and Complement inhibition

Priorities regarding activities that the HBA-USA should undertake

- Promote the activities of the Alumni Association of the Student Exchange Program (AASEP)
- Build processes and organize the activities of this program to ensure a database is developed and it is defined how new students can participate in the UoC-BU exchange program.
- Support the financial activities of HBA-USA and AASEP (tax filing, agent filing, subscriptions, mailbox)

Time commitment that the candidate can take during his term as a BD member:

Less than 4 hours/month ___
4-10 hours/month x
10-20 hours/month ___
More than 20 hours/month ___

Highest position that the candidate would prefer to hold in the BD (more than one can be selected):

President ___
Vice-President ___
General Secretary ___
Treasurer x
Appointed Secretary ___
Councilor x
Any of the above ___

Additional comments that the Candidate wants to make:

Andreas was introduced to HBA-USA in 2011 and from 2017-2019 served as Councilor and since 2019 is the Treasurer of HBA-USA. Andreas manages all Treasurer activities (taxes, non-profit status, mailbox, registration inquiries).
During the second term Andreas worked with Dr. Zannis to establish AASEP under the umbrella of HBA-USA.
During the third term Andreas supported AASEP to further expand and managed the scholarships awarded by AASEP and HBAUSA.